Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors

US6545002B1 · kind B1 · utility

Assignees

• University of Virginia Patent Foundation · US
• National Institutes of Health, Office of Technology Transfer · US

Inventors

• Joel M. Linden · Charlottesville, US
• Kenneth A. Jacobson · Silver Spring, US
• Yong Chul Kim · Gwangju, KR

Key dates

• Filing date: Feb 17, 2000
• Grant date: Apr 8, 2003
• Expiry date: Feb 17, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds having the formula I: X is (C1-C8)alkylene, (C2-C8)alkenylene, (C2-C8)alkynylene, wherein one of the carbon atoms in the alkylene, alkenylene or alkynylene groups is optionally replaced with a group having the formula —O—, —N(R4)C(O)—, —OC(O—, S—, —S(O)—or —SO2—, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising compounds having the formula I. The compounds of the invention are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents for treatment of diseases that are mediated by A2B adenosine receptors.